| scholarly article | Q13442814 |
| P50 | author | Vito Racanelli | Q56678833 |
| Roberto Ria | Q40438358 | ||
| Sebastiano Cicco | Q63198754 | ||
| Antonio Giovanni Solimando | Q64010770 | ||
| Matteo C Da Vià | Q82451904 | ||
| Andreas Beilhack | Q89647079 | ||
| Giuseppe Di Lernia | Q89834623 | ||
| Patrizia Leone | Q89834624 | ||
| P2093 | author name string | Hermann Einsele | |
| Angelo Vacca | |||
| Maria Antonia Frassanito | |||
| K Martin Kortüm | |||
| Giuseppe Ranieri | |||
| Vanessa Desantis | |||
| Leo Rasche | |||
| Ilaria Saltarella | |||
| Assunta Melaccio | |||
| Donato Giannico | |||
| Arcangelo Morizio | |||
| Julia Delgado Tascon | |||
| P2860 | cites work | Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma | Q91621613 |
| Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma | Q91669350 | ||
| The bone marrow microenvironment at single-cell resolution | Q93012764 | ||
| Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib | Q24594790 | ||
| Treatment of relapsed and refractory multiple myeloma | Q26749180 | ||
| Effect of AURKA Gene Expression Knockdown on Angiogenesis and Tumorigenesis of Human Ovarian Cancer Cell Lines | Q51725708 | ||
| Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical study. | Q51732175 | ||
| Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). | Q52540929 | ||
| Targeting vasculogenesis to prevent progression in multiple myeloma | Q52885536 | ||
| Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. | Q52955942 | ||
| Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome | Q53113011 | ||
| Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial | Q53127020 | ||
| Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma | Q53170046 | ||
| Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation | Q53203772 | ||
| A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. | Q53246749 | ||
| Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing-Neel syndrome. | Q53506683 | ||
| Inhibition of lymphocyte function associated antigen 1 by LFA878 induces apoptosis in multiple myeloma cells and is associated with downregulation of the focal adhesion kinase/phosphatidylinositol 3 kinase/Akt pathway. | Q53530269 | ||
| Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma | Q54110134 | ||
| A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target. | Q54323070 | ||
| BRAF Inhibition in Refractory Hairy-Cell Leukemia | Q54509211 | ||
| Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma. | Q54986945 | ||
| Targeting MET in cancer therapy. | Q54987450 | ||
| Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma | Q56973515 | ||
| PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs | Q57035464 | ||
| The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells | Q40318843 | ||
| Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. | Q40633414 | ||
| Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease | Q40742165 | ||
| Significance of VLA-4-VCAM-1 interaction and CD44 for transendothelial invasion in a bone marrow metastatic myeloma model | Q40874434 | ||
| Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma | Q41138218 | ||
| Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing | Q41436943 | ||
| Impacts of survivin and caspase-3 on apoptosis and angiogenesis in oral cancer | Q41615847 | ||
| Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma | Q41700620 | ||
| Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma | Q41984297 | ||
| Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. | Q42050819 | ||
| Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen | Q42427616 | ||
| Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib | Q42598619 | ||
| Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity | Q42696060 | ||
| Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p | Q42781523 | ||
| Inhibiting MEK in MAPK pathway-activated myeloma | Q42881301 | ||
| Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy | Q43024864 | ||
| Dual role of fatty acid-binding protein 5 on endothelial cell fate: a potential link between lipid metabolism and angiogenic responses | Q43087961 | ||
| Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma | Q43662977 | ||
| Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma | Q44088841 | ||
| Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials | Q44918517 | ||
| Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients | Q45129141 | ||
| Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival | Q46253134 | ||
| MUC1-C is a target in lenalidomide resistant multiple myeloma | Q46345708 | ||
| A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. | Q46480213 | ||
| Bortezomib or high-dose dexamethasone for relapsed multiple myeloma | Q46549268 | ||
| Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling | Q46868726 | ||
| CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma | Q47125786 | ||
| A gene expression signature for high-risk multiple myeloma. | Q47590597 | ||
| JAM-A as a prognostic factor and new therapeutic target in multiple myeloma | Q47610951 | ||
| Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. | Q47637765 | ||
| Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment. | Q47699487 | ||
| Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma | Q47800329 | ||
| Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. | Q47894196 | ||
| Evolutionary biology of high-risk multiple myeloma | Q47913337 | ||
| CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma | Q48188365 | ||
| Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma | Q48214002 | ||
| Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition. | Q48236775 | ||
| Hypoxia modulates the purine salvage pathway and decreases red blood cell and supernatant levels of hypoxanthine during refrigerated storage | Q49305174 | ||
| First targeted therapy in multiple myeloma | Q49387225 | ||
| Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia. | Q49388828 | ||
| CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma | Q49660927 | ||
| Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. | Q50050288 | ||
| MRD in multiple myeloma: more questions than answers? | Q50057591 | ||
| The bone-marrow niche in MDS and MGUS: implications for AML and MM. | Q50114615 | ||
| Interpretation of cytogenetic results in multiple myeloma for clinical practice | Q26777803 | ||
| New criteria for response assessment: role of minimal residual disease in multiple myeloma | Q27027512 | ||
| Targeting the BRAF V600E mutation in multiple myeloma | Q27852220 | ||
| Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma | Q28266655 | ||
| Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells | Q28303091 | ||
| Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma | Q33348936 | ||
| Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression | Q33376149 | ||
| Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma | Q33377526 | ||
| A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma | Q33401596 | ||
| Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents | Q33401759 | ||
| How I treat plasma cell leukemia | Q33402555 | ||
| Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial | Q33410172 | ||
| Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. | Q33411708 | ||
| High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-l | Q33416028 | ||
| A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma | Q33426534 | ||
| Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma | Q33621587 | ||
| CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma | Q33703097 | ||
| Antitumor activity of thalidomide in refractory multiple myeloma | Q33880642 | ||
| Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. | Q33885555 | ||
| Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma | Q33948719 | ||
| Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation | Q33952805 | ||
| Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group | Q33956990 | ||
| A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival | Q33957196 | ||
| Angiogenesis inhibitors: current strategies and future prospects | Q34056376 | ||
| Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy | Q34122646 | ||
| Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. | Q34209320 | ||
| International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. | Q34241661 | ||
| International staging system for multiple myeloma | Q34408882 | ||
| Curing myeloma at last: defining criteria and providing the evidence | Q34508313 | ||
| Genomic complexity of multiple myeloma and its clinical implications | Q34537571 | ||
| Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America | Q34585268 | ||
| CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance | Q57191729 | ||
| Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes | Q57787647 | ||
| Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | Q57904272 | ||
| Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du M | Q58051897 | ||
| Hexokinase-2 Expression in MET-positive FDG-negative Multiple Myeloma | Q58617088 | ||
| The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells | Q60203614 | ||
| Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial | Q60913436 | ||
| Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses | Q60943043 | ||
| A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis | Q61905635 | ||
| The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma | Q61905638 | ||
| Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. | Q64929020 | ||
| Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. | Q64931827 | ||
| Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44 | Q71709369 | ||
| Prognostic value of bone marrow angiogenesis in multiple myeloma | Q74216118 | ||
| Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 | Q80530381 | ||
| Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma | Q81251723 | ||
| Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients | Q83179100 | ||
| Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets | Q85026964 | ||
| Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma | Q88197211 | ||
| Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods | Q88666887 | ||
| Deep Profiling of the Immune System of Multiple Myeloma Patients Using Cytometry by Time-of-Flight (CyTOF) | Q88802702 | ||
| Protocol for M3P: A Comprehensive and Clinical Oriented Targeted Sequencing Panel for Routine Molecular Analysis in Multiple Myeloma | Q88802746 | ||
| Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network | Q90225967 | ||
| Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma | Q90318029 | ||
| Spectrum and functional validation of PSMB5 mutations in multiple myeloma | Q90351167 | ||
| Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients | Q90468255 | ||
| EMT Transition States during Tumor Progression and Metastasis | Q90804085 | ||
| Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients | Q91409167 | ||
| Multiple myeloma: evolving genetic events and host interactions | Q34624999 | ||
| Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: a systematic review and meta-analysis | Q35104606 | ||
| Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r | Q35180069 | ||
| BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis | Q35244900 | ||
| The role of adhesion molecules in multiple myeloma | Q35663030 | ||
| The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications | Q35912178 | ||
| A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. | Q35984702 | ||
| Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma | Q36014687 | ||
| Myeloma as a model for the process of metastasis: implications for therapy | Q36079800 | ||
| Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? | Q36382187 | ||
| Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia | Q36509641 | ||
| 11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement | Q36510870 | ||
| Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group | Q36839385 | ||
| SnapShot: Multiple Myeloma | Q36894316 | ||
| Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities | Q36941047 | ||
| The treatment of relapsed and refractory multiple myeloma | Q37007400 | ||
| Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group | Q37037265 | ||
| CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation | Q37127055 | ||
| The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance | Q37152481 | ||
| Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling | Q37171812 | ||
| Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications | Q37417591 | ||
| Heterogeneity of genomic evolution and mutational profiles in multiple myeloma | Q37528285 | ||
| [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values | Q37541868 | ||
| Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. | Q37552061 | ||
| Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management | Q37623809 | ||
| Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. | Q37724272 | ||
| Adhesion molecules--The lifelines of multiple myeloma cells | Q37736671 | ||
| Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. | Q37835571 | ||
| Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach | Q37928806 | ||
| The genetic architecture of multiple myeloma. | Q38001913 | ||
| Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation | Q38268782 | ||
| Targeting the bone marrow microenvironment in multiple myeloma. | Q38289041 | ||
| Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. | Q38315523 | ||
| Multiple myeloma as a model for the role of bone marrow niches in the control of angiogenesis | Q38331689 | ||
| Number of expressed cancer/testis antigens identifies focal adhesion pathway genes as possible targets for multiple myeloma therapy. | Q38343521 | ||
| The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling. | Q38656507 | ||
| Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma | Q38665985 | ||
| How I treat extramedullary myeloma | Q38672673 | ||
| Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients | Q38686915 | ||
| Trends in overall survival and costs of multiple myeloma, 2000-2014. | Q38779003 | ||
| Primary Plasma Cell Leukemia: Identity Card 2016. | Q38781794 | ||
| Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials | Q38789282 | ||
| Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors. | Q38808490 | ||
| E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271. | Q38821948 | ||
| Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. | Q38822625 | ||
| International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma | Q38832525 | ||
| Emerging antibodies for the treatment of multiple myeloma | Q38838239 | ||
| Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. | Q38852886 | ||
| Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons | Q38859727 | ||
| Genomics of Multiple Myeloma. | Q38905598 | ||
| Microenvironment drug resistance in multiple myeloma: emerging new players | Q38913083 | ||
| Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies | Q39019022 | ||
| IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). | Q39065368 | ||
| Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma. | Q39134426 | ||
| Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group | Q39214847 | ||
| The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications | Q39472801 | ||
| Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. | Q39560208 | ||
| Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion | Q39562168 | ||
| Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling | Q39690768 | ||
| Induction of angiogenesis by normal and malignant plasma cells. | Q39870744 | ||
| Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma | Q39930099 | ||
| Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein | Q39970575 | ||
| Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma | Q40232283 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P577 | publication date | 2019-07-09 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Journal of Clinical Medicine | Q27724774 |
| P1476 | title | High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment | |
| P478 | volume | 8 |
| Q89834625 | Bortezomib Treatment Modulates Autophagy in Multiple Myeloma |
| Q90419584 | Current Perspectives in Cancer Immunotherapy |
| Q92636657 | HB-EGF-EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma |
| Q92636053 | Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma |
Search more.